- Number of people
- 101 (79.21% female)
- People with ≥2 records
- 10.89%
- Median duration from first to last measurement
- 0.81 years
Certolizumab [Mass/volume] in Serum or Plasma by Immunoassay
Coding
Definition
- OMOP Concept ID
- 36303722— open in OHDSI Athena.
- Part of collection
- Certolizumab with 0 other OMOP concept — open in OHDSI Athena.
OMOP mapping QC
| OMOP concept ID | Test name | Measurement unit (harmonized unit) | N people | N records | Missing measurement value | Harmonized value distribution |
Test outcome
NA
N
A
AA
L
LL
H
HH
|
|---|---|---|---|---|---|---|---|
| 36303722 | s-serto | ug/ml (mg/l) | 62 | 72 | 0.00% |
|
|
| 36303722 | s-serto | mg/l (mg/l) | 33 | 35 | 0.00% |
|
|
| 36303722 | s-serto | — (—) | 10 | 11 | 100.00% | Distribution not available |
Cohort
- Number of people
- 101 (79.21% female)
Year of birth distribution
Age at first measurement
Age at last measurement
Age at start of registry
Duration from first to last measurement
Statistics
- People with ≥2 records
- 10.89%
- Median number of measurements per person
- 1.0
- Median duration from first to last measurement
- 0.81 years
Number of measurements over the years
Number of measurements per person
Distribution of lab values
Reference range
N people
N records
—
92
108
/Kaikki
10
11
Value range per person
LabWAS
Endpoint
People with measurements
Mean N measurements
Mean measured value
Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
65
16
22.03
56.15
1.2
1.1
27.54
34.56
mg/l
1.16
58
16
64
16
21.77
55.26
1.3
1.1
27.89
34.56
mg/l
1.07
58
16
30
10
18.69
27.30
1.2
1.1
29.16
32.20
mg/l
—
25
10
21
62
3.28
5.79
1.4
1.1
32.21
27.08
mg/l
0.58
21
54
15
47
3.13
3.91
1.0
1.3
21.22
29.37
mg/l
1.12
15
42
15
62
2.32
2.31
1.1
1.2
23.97
29.24
mg/l
0.78
15
56
16
67
1.92
1.57
1.0
1.2
23.24
28.12
mg/l
0.64
16
60
5
68
0.38
1.44
1.2
1.2
29.20
28.58
mg/l
—
5
62
14
47
1.86
1.23
1.1
1.2
25.61
30.17
mg/l
0.61
14
41
13
70
1.75
1.05
1.1
1.2
29.53
28.29
mg/l
0.07
13
64
12
63
1.74
0.95
1.2
1.2
19.91
30.35
mg/l
1.80
12
58
17
74
1.53
0.83
1.1
1.2
25.40
28.87
mg/l
0.40
17
66
10
35
1.67
0.67
1.1
1.2
24.85
30.54
mg/l
—
10
30
8
50
1.60
0.61
1.1
1.2
23.11
29.40
mg/l
—
8
45
8
55
1.44
0.42
1.1
1.3
35.50
28.55
mg/l
—
8
50
12
70
1.28
0.27
1.2
1.2
29.09
29.06
mg/l
0.00
12
62
0
13
0.00
0.21
0.0
1.1
—
24.23
—
0
13
0
13
0.00
0.20
0.0
1.2
—
23.48
—
0
13
0
14
0.00
0.20
0.0
1.4
—
24.43
—
0
14
14
81
1.19
0.18
1.1
1.2
24.35
29.03
mg/l
0.59
14
74
10
76
0.84
0.14
1.2
1.2
33.20
28.26
mg/l
—
10
70
6
53
1.10
0.09
1.2
1.2
24.83
29.11
mg/l
—
6
47
7
72
0.87
0.07
1.3
1.2
34.86
28.99
mg/l
—
7
67
9
83
1.03
0.07
1.0
1.2
34.64
27.51
mg/l
—
9
75
13
80
1.10
0.06
1.2
1.2
20.73
30.54
mg/l
1.68
13
73
10
85
1.07
0.01
1.0
1.2
33.38
27.65
mg/l
—
10
77
0
6
0.00
0.00
0.0
1.2
—
26.75
—
0
6
0
5
0.00
0.00
0.0
1.0
—
26.50
—
0
5
0
6
0.00
0.00
0.0
1.2
—
26.75
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
23.70
—
0
5
8
60
0.92
-0.00
1.1
1.2
30.13
26.76
mg/l
—
8
55
0
6
0.00
-0.00
0.0
1.2
—
26.75
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
26.50
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
26.75
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
29.00
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
23.36
—
0
7
0
9
0.00
-0.00
0.0
1.4
—
25.94
—
0
9
0
5
0.00
-0.00
0.0
1.8
—
28.90
—
0
5
9
64
0.95
-0.00
1.1
1.2
27.12
26.72
mg/l
—
9
59
0
7
0.00
-0.00
0.0
1.1
—
26.64
—
0
7
Congenital malformations of the musculoskeletal system, not elsewhere classified, including avohilmo
0
5
0.00
-0.00
0.0
1.0
—
26.50
—
0
5